Table 1.
Summary descriptives of clinical and biological characteristics of all patients treated.
| n = 82 | n | |
|---|---|---|
| MYCN: | 82 | |
| A | 21 (25.6%) | |
| NA | 61 (74.4%) | |
| Chemotherapy cycles: | 82 | |
| 5 | 13 (15.9%) | |
| >5 | 69 (84.1%) | |
| ASCT: | 82 | |
| No | 71 (86.6%) | |
| Yes | 11 (13.4%) | |
| RDT: | 82 | |
| No | 56 (68.3%) | |
| Yes | 26 (31.7%) | |
| MRD: | 82 | |
| No | 70 (85.4%) | |
| Yes | 12 (14.6%) | |
| Age at diagnosis (y) | 3.0 [0.6; 13.0] | 82 |
| Age at treatment initiation (y) | 3.9 [1.4; 13.8] | 82 |
| Stage: | 82 | |
| 3 | 1 (1.2%) | |
| 4 | 81 (98.8%) | |
| Induction Regimen: | 82 | |
| mN7 | 16 (19.5%) | |
| GPOH NB2004 | 6 (7.3%) | |
| SIOPEN HR-NB-01 | 10 (12.2%) | |
| COG 3973 | 5 (6.1%) | |
| Chinese protocols | 40 (48.8%) | |
| Russian HR-NB protocols | 1 (1.2%) | |
| GALOP protocol | 2 (2.4%) | |
| CCG | 2 (2.4%) |
Legend: MYCN status: A = amplified; NA = non-amplified. ASCT = autologous stem-cell transplantation. MRD = minimal residual disease (Bone marrow). Age at DX = age at diagnosis; Age at Treat. = age at immunotherapy initiation; all in y = years.